• 1
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333:14371443.
  • 2
    Heaney RP, Yates AJ, Santora AC 1997 Bisphosphonate effects and the bone remodeling transient J Bone Miner Res 12:11431151.
  • 3
    Heaney RP 1994 The bone remodeling transient: Implications for the interpretation of clinical studies of bone mass change J Bone Miner Res 9:15151523.
  • 4
    Storm T, Steiniche T, Thamsborg G, Melsen F 1993 Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis J Bone Miner Res 8:199208.
  • 5
    Evequoz V, Trechsel U, Fleisch H 1985 Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes Bone 6:439444.
  • 6
    Guenther HL, Guenther HE, Fleisch H 1981 The effects of 1-hydroxyethane-1, 1-diphosphonate and dichloromethane-diphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells Biochem J 196:293301.
  • 7
    Guenther HL, Guenther HE, Fleisch H 1981 The influence of 1-hydroxyethane-1, 1-diphosphonate and dichloromethane-diphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen Biochem J 196:303310.
  • 8
    Tsuchimoto M, Azuma Y, Higuchi O, Sugimoto I, Hirata N, Kiyoki M, Yamamoto I 1994 Alendronate modulates osteogenesis of human osteoblastic cells in vitro Jpn J Pharm 66:2533.
  • 9
    Giuliani N, Girasole G, Pedrazzoni M, Passeri G, Gatti C, Passeri M 1995 Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures J Bone Miner Res 10 (Suppl 1):S171.
  • 10
    Balena R, Toolan BC, Shea M, Markatos A, Meyers ER, Lee SD, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of two year treatment with the aminobisphosphonate ALN on bone metabolism, bone histomorphometry and bone strength in ovariectomized non-human primates J Clin Invest 92:25772586.
  • 11
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH III 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis N Engl J Med 323:7379.
  • 12
    Riggs BL, Hodgson SF, O'Fallon WM 1990 Effect of fluoride treatment on the fracture rate in post-menopausal women with osteoporosis N Engl J Med 322:802809.
  • 13
    Kleerekoper M, Peterson E, Nelson DA, Phillips E, Schorck MA, Tilley BC, Parfitt AM 1991 A randomized trial of sodium fluoride as a treatment for post-menopausal osteoporosis Osteoporos Int 1:155162.
  • 14
    Cummings SR, Black DM, Vogt TM 1996 Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs J Bone Miner Res 11 (Suppl 1):S102.
  • 15
    Delmas PD 1997 Epidemiology of osteoporosis: The role of bone mass, structure and turnover as determinants of fractures Bone 20(Suppl):1S.
  • 16
    Parfitt Am 1991 Use of bisphosphonates in the prevention of bone loss and fractures Am J Med 91(Suppl 5B):42S46S.
  • 17
    Grynpas MD, Acito A, Dimitriu M, Mertz BP, Very JM 1991 Changes in bone mineralization, architecture and mechanical properties due to long-term (1 year) administration of pamidronate (APD) to adult dogs Osteoporos Int 2:7481.
  • 18
    Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells Endocrinology 136:36323638.
  • 19
    Hodsman AB 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surface Bone 14:523527.
  • 20
    Lindsay R, Cosman F, Dempster DW, Formica C, Nieves J 1997 Parathyroid hormone increases vertebral bone mass and may reduce vertebral fractures in estrogen treated postmenopausal women with osteoporosis Bone 20(Suppl):19S.
  • 21
    Hodsman AB, Fraher LJ, Watson PH, Osdoby T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis J Clin Endocrinol 82:620628.
  • 22
    Tucci JR, Tonino RP, Emkey RD, Peverley CA, Kher U, Santora AC for the U.S. Alendronate Phase III Osteoporosis Treatment Study Group 1996 Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis Am J Med 101:488501.
  • 23
    Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B Alendronate stimulation of nocturnal parathyroid hormone secretion: A mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 108:230238.
  • 24
    Bradbeer JM, Arlot ME, Meunier PJ, Reeve J 1992 Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone Clin Endocrinol 37:282289.
  • 25
    Dempster DW, Parisien M, Liang X-G, Schnitzer M, Shen V, Silverberg S, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP 1996 Bone histomorphometry in postmenopausal women with primary hyperparathyroidism J Bone Miner Res 11 (Suppl 1):S98.
  • 26
    Meng XW, Liang XG, Birchman R, Wu DD, Dempster DW, Lindsay R, Shen V 1996 Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats J Bone Miner Res 11:421429.
  • 27
    Qi H, Li M, Wronski TJ 1995 A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats J Bone Miner Res 10:948955.